Logo Image
News|Podcasts|January 30, 2025

The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations

Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.

In this episode of the Pharmaceutical Executive podcast, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses:

  • The challenges of addressing fertility misinformation on social media
  • The importance of providing accurate and reliable information
  • The importance of consulting with healthcare professionals
  • The ethical considerations of using social media to share personal and professional experiences
  • and so much more!

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Read more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Pimjetmi
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Read more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more